Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2757 results

Clinical Trials / Dec 22, 2025

Secukinumab Open Label Roll-over Extension Protocol
Clinical Trials / Mar 03, 2026

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Clinical Trials / Jun 29, 2025

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Clinical Trials / Dec 22, 2025

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
General Meetings
Board of Directors
Biography / Mar 03, 2026

Charles Swanton
Media Library / Mar 03, 2026

Charles Swanton, M.B.Ph.D.
Press release / Mar 06, 2026

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as…
Press release / Mar 06, 2026

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut

Die Aktionärinnen und Aktionäre genehmigten die 29. Dividendenerhöhung in Folge. Für 2025 wird die Dividende auf CHF 3.70 (+5,7%) je Aktie erhöht, was einer Rendite von 3,0% entspricht¹Die…

‹ Previous page
1
…
4
5
6
7
8
9
10
…
276
› Next page